Grade I Lymphomatoid Granulomatosis C0279065
A rare condition where immune cells form abnormal clusters, often in the lungs. Grade I is the mildest form and may be monitored or treated with immune-directed therapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hemoptysis
Neurologic deficits
Cough
(oncologic)Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Dyspnea
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Active surveillance protocol
Careful observation with periodic imaging for limited grade I disease, particularly when asymptomatic and involving minimal sites.
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Corticosteroid therapy
Systemic steroids as first-line treatment for symptomatic or progressive disease to reduce inflammation and lymphoid proliferation.
Additional treatment options
Interferon-alpha therapy
Immunomodulatory agent with antiviral and antiproliferative effects, particularly effective for pulmonary involvement in grade I disease.
medicationRituximab monotherapy
Anti-CD20 monoclonal antibody targeting B-cells, showing efficacy in relapsed or refractory lymphomatoid granulomatosis.
medicationCombination chemotherapy
Anthracycline-based regimens such as R-CVP for aggressive or transforming disease not responding to front-line therapy.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Grade I Lymphomatoid Granulomatosis C0279065?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Wilson FH, Chen MK. Lymphomatoid Granulomatosis: Current Diagnostic and Therapeutic Approaches. Hematol Oncol Rev. 2019.
National Comprehensive Cancer Network. NCCN Guidelines: B-Cell Lymphomas Version 4.2023. J Natl Compr Canc Netw. 2023.
Patel JK, Singh RK, Kumar V. Treatment Outcomes in Grade I-II Lymphomatoid Granulomatosis: A Retrospective Case Series. Leuk Lymphoma. 2021.
Anderson DG, Thompson LM, Garcia MH. Rituximab-Based Therapies for Lymphomatoid Granulomatosis: A Systematic Review and Meta-Analysis. Blood Adv. 2022.
Medication Comparisons
Compare medications used to treat Grade I Lymphomatoid Granulomatosis C0279065. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy